Compared with apatinib monotherapy, those treated with combination strategy displayed a lower tumor growth, mainly via higher CD8+ T cells infiltration, reduced Treg and MDSC infiltration and lower PD-1/PD-L1 expression (53). The gene discussed is CD8A; the disease is neoplasm.